Table 3 Diagnostic agreement of TST and QFT-IT (κ) *
QFT-IT + | QFT-IT - | Total | κ | |
|---|---|---|---|---|
All participants | 0.48 | |||
TST + | 26 (14.7) | 11 (6.2) | 37 | |
TST - | 23 (13.0) | 117 (66.1) | 140 | |
Total | 49 | 128 | 177 | |
Immunocompetent group | 0.57 | |||
TST + | 17 (20.0) | 8 (9.4) | 25 | |
TST - | 7 (8.2) | 53 (62.4) | 60 | |
Total | 24 | 61 | 85 | |
Immunocompromised group | 0.38 | |||
TST+ | 9 (9.8) | 3 (3.3) | 12 | |
TST - | 16 (17.4) | 64 (69.6) | 80 | |
Total | 25 | 67 | 92 | |
Immunocompromised group* | 0.40 | |||
TST+* | 14 (15.2) | 11 (12.0) | 25 | |
TST -* | 11 (12.0) | 56 (60.9) | 67 | |
Total | 25 | 67 | 92 |